In This Article:
Alcon ALC recently announced that its Clareon Vivity intraocular lens (IOL), featuring extended depth of focus (EDOF) technology, has received CE Mark approval. The lens, made from Alcon's advanced Clareon material, is set for commercial rollout across Europe in early second-quarter 2025, expanding visual possibilities for patients.
This milestone highlights Alcon's commitment to enhancing vision care, offering patients a premium presbyopia-correcting solution. The introduction of Clareon Vivity IOL marks a significant advancement in ocular health technology, bringing clearer vision to those with age-related near-vision loss.
Likely Trend of ALC Stock Following the News
Shares of the company jumped nearly 2% and closed at $92.35 yesterday, banking on its other positive updates. However, in the past six months, ALC’s shares have lost 6.5% compared with the industry’s 8.4% decline. The S&P 500 declined 0.6% in the same time frame.
The company’s Surgical segment continues to gain from its diverse portfolio and incremental innovation. Within the segment, Alcon is gaining synergies for its cataract consumables business due to various product launches. We expect the market sentiment toward the ALC stock to remain positive surrounding the latest agreement.
Meanwhile, ALC currently has a market capitalization of $44.67 billion. The company delivered an earnings surprise of 2.9% in the last reported quarter.
Image Source: Zacks Investment Research
More on ALC’s Clareon Vivity IOL
Clareon Vivity IOL is designed to address presbyopia, a common age-related condition that affects near vision, making tasks like reading or using a phone difficult. Unlike traditional monofocal lenses, which provide clear vision at only one distance, Clareon Vivity offers EDOF, allowing patients to see clearly at multiple distances.
Clareon Vivity IOL is made from a high-quality material with minimal haze and glistenings, offering sharp, clear vision. The lens features a proprietary edge design to reduce glare and posterior capsular opacification, while its STABLEFORCE Haptics ensure stability in the eye. Using X-WAVE Technology, it extends the focal range for better vision at multiple distances. Compared with monofocal lenses, it reduces the need for glasses and improves intermediate and near vision without compromising contrast sensitivity.
With the CE Mark approval for Clareon Vivity and Clareon Vivity Toric, surgeons in Europe now have access to the complete Clareon IOL portfolio to address various patient needs. This includes Clareon Monofocal, Clareon Toric, Clareon PanOptix and Clareon PanOptix Toric, all available in foldable options with ultraviolet absorption and blue light filtering.